Quadria Capital

Quadria targets growth-stage and late-stage healthcare companies in Asia with strong market differentiation and scalable models. The firm takes an industrial approach to value creation, leveraging an in-house operational excellence team. Investments span healthcare delivery, life sciences, medical devices, diagnostics, and digital health.

Quadria invests primarily in India and Southeast Asia. The firm maintains offices in Singapore, New Delhi, Ho Chi Minh City, and Jakarta. Portfolio companies serve markets across India, Malaysia, the Philippines, Uzbekistan, and Nepal.

Available sources do not detail Quadria's co-investment posture. The firm typically structures direct, control or significant-minority investments and has not publicly described a co-investment club or LP co-invest program.

Quadria invests across the healthcare ecosystem: hospitals, dialysis networks, eye care chains, pharmaceutical contract research and manufacturing (CRDMO), orthopedic device CDMOs, digital health platforms, topical drugs, and personal hygiene. The firm explicitly targets companies that can become regional market leaders.

Quadria has not publicly disclosed its investment committee composition or named its managing partners on the current website. The firm describes one of the largest dedicated healthcare investment teams in Asia, but individual decision-makers are not identified in primary sources.